全文获取类型
收费全文 | 6924篇 |
免费 | 465篇 |
国内免费 | 57篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 162篇 |
妇产科学 | 53篇 |
基础医学 | 366篇 |
口腔科学 | 31篇 |
临床医学 | 341篇 |
内科学 | 2750篇 |
皮肤病学 | 13篇 |
神经病学 | 68篇 |
特种医学 | 293篇 |
外科学 | 2087篇 |
综合类 | 49篇 |
现状与发展 | 1篇 |
预防医学 | 187篇 |
眼科学 | 16篇 |
药学 | 152篇 |
中国医学 | 9篇 |
肿瘤学 | 848篇 |
出版年
2024年 | 4篇 |
2023年 | 531篇 |
2022年 | 859篇 |
2021年 | 708篇 |
2020年 | 665篇 |
2019年 | 467篇 |
2018年 | 380篇 |
2017年 | 397篇 |
2016年 | 315篇 |
2015年 | 341篇 |
2014年 | 729篇 |
2013年 | 521篇 |
2012年 | 251篇 |
2011年 | 93篇 |
2010年 | 255篇 |
2009年 | 229篇 |
2008年 | 58篇 |
2007年 | 90篇 |
2006年 | 80篇 |
2005年 | 75篇 |
2004年 | 30篇 |
2003年 | 49篇 |
2002年 | 46篇 |
2001年 | 44篇 |
2000年 | 43篇 |
1999年 | 37篇 |
1998年 | 49篇 |
1997年 | 38篇 |
1996年 | 39篇 |
1995年 | 3篇 |
1994年 | 7篇 |
1993年 | 1篇 |
1992年 | 3篇 |
1991年 | 2篇 |
1988年 | 1篇 |
1983年 | 2篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 2篇 |
排序方式: 共有7446条查询结果,搜索用时 109 毫秒
1.
《Clinical therapeutics》2022,44(3):403-417.e6
PurposeEntecavir (ETV) and tenofovir disoproxil fumarate (TDF) are both recommended as first-line treatments for patients with chronic hepatitis B virus (CHB) infection according to international HBV treatment guidelines. However, recent studies reported conflicting results regarding the preferred antiviral in the prevention of hepatocellular carcinoma (HCC). This cohort study aimed to investigate this issue by using Taiwan's National Health Insurance Research Database, wherein a “finite” but not life-long treatment policy was applied.MethodsFrom January 2008 to December 2013, a total of 12,388 consecutive adult patients with CHB who received a finite course of TDF treatment (n = 1250) or ETV treatment (n = 11,138) were analyzed through screening for study eligibility followed by the 1:4 propensity score matching method.FindingsIn the entire cohort, the annual incidence and survival between the ETV and TDF groups were not significantly different regarding HCC occurrence (2.05 vs 2.74 per 100 patient-years [PY]; P = 0.055; hazard ratio [HR], 0.975; log-rank, P = 0.966), cirrhosis-related complications (1.9 vs 2.4 per 100 PY; P = 0.149; HR, 0.869; log-rank, P = 0.388), or all-cause mortality (2.16 vs 1.6 per 100 PY; P = 0.119; HR, 0.831; log-rank, P = 0.342), respectively. Propensity score matching analyses yielded similar results regarding HCC occurrence, cirrhosis-related complications, and all-cause mortality. In addition, these findings were consistently reproduced in the subgroups of patients with chronic hepatitis and cirrhosis that developed before antiviral treatment.ImplicationsETV and TDF did not significantly differ in prevention of HCC occurrence or reduction of cirrhosis-related complications and all-cause mortality in patients with CHB receiving a finite period of treatment. 相似文献
2.
3.
《HPB : the official journal of the International Hepato Pancreato Biliary Association》2022,24(8):1201-1216
BackgroundPancreatic ductal adenocarcinoma (PDAC) has poor survival. Current treatments offer little likelihood of cure or long-term survival. This systematic review evaluates prognostic models predicting overall survival in patients diagnosed with PDAC.MethodsWe conducted a comprehensive search of eight electronic databases from their date of inception through to December 2019. Studies that published models predicting survival in patients with PDAC were identified.Results3297 studies were identified; 187 full-text articles were retrieved and 54 studies of 49 unique prognostic models were included. Of these, 28 (57.1%) were conducted in patients with advanced disease, 17 (34.7%) with resectable disease, and four (8.2%) in all patients. 34 (69.4%) models were validated, and 35 (71.4%) reported model discrimination, with only five models reporting values >0.70 in both derivation and validation cohorts. Many (n = 27) had a moderate to high risk of bias and most (n = 33) were developed using retrospective data. No variables were unanimously found to be predictive of survival when included in more than one study.ConclusionMost prognostic models were developed using retrospective data and performed poorly. Future research should validate instruments performing well locally in international cohorts and investigate other potential predictors of survival. 相似文献
4.
5.
6.
7.
8.
《Transplant immunology》2015,33(3):175-178
IntroductionVascular smooth muscle cells (VSMCs) and monocyte–macrophages play a central role during the development of chronic allograft injury, which still remains an important challenge in organ transplantation. Inflammation, fibrosis and accelerated arteriosclerosis are typical features for chronic allograft injury. Growth factors participate in cell proliferation, differentiation and migration in this pathological process.ObjectiveHere we studied the role of epidermal growth factor receptor (EGFR) in VSMC and monocyte–macrophage function in vitro. EGFR inhibition by erlotinib, a selective EGF tyrosine kinase inhibitor, was studied in VSMC proliferation and migration as well as monocyte–macrophage proliferation and differentiation.Materials and methodsRat coronary artery SMCs were used for VSMC studies. As a model for monocyte–macrophage proliferation and differentiation human monocytic cell line U937 was used. Phorbol ester TPA was used to induce these cells to differentiate into macrophages.ResultsPlatelet-derived growth factor (PDGF)-B, a known VSMC inducer, caused 2.1-fold stimulation in VSMC proliferation compared to non-stimulated VSMC. Erlotinib prevented this VSMC proliferation in a dose-dependent manner, p < 0.001 in all groups compared to controls. PDGF-B stimulation increased VSMC migration to 2.5-fold when compared with non-stimulated cells. Erlotinib decreased VSMC migration dose-dependently and this effect was significant with all doses, p < 0.05. Erlotinib inhibited dose-dependently the proliferation of U937 monocytic cells, p < 0.001. Erlotinib prevented also TPA-induced macrophage differentiation in a dose-dependent way, p < 0.05.DiscussionErlotinib significantly prevents VSMC proliferation and migration in vitro. Erlotinib inhibited also significantly both monocyte proliferation and differentiation. Our data suggest that EGFR inhibition in VSMC and monocyte function has beneficial effects on chronic allograft injury. 相似文献
9.
10.